ReviewFood science & nutrition2025
Elucidating the Anticancer Mechanisms of Tetrahydroxycurcumin: A Comprehensive Review of Preclinical Studies.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating the Anticancer Mechanisms of Tetrahydroxycurcumin: A Comprehensive Review of Preclinical Studies.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One significant reductive metabolite of curcumin, tetrahydroxycurcumin (THC), is a promising oncology candidate because of its multifunctional bioactivities. Preclinical data indicate that THC has a strong anti-inflammatory, antioxidant, and anticancer profile, and as such, it is a better alternative to curcumin in treatment. Mechanistically, THC regulates important transcriptional factors that are involved in tumorigenesis, specifically nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1). Uncontrolled proliferation, inflammation, and resistance to apoptosis have been linked to aberrant activation of these pathways. Inhibition of NF-kB and AP-1 induced by THC suppresses cancer cell survival signaling and triggers apoptotic cell death. Simultaneously, THC inhibits the action of matrix metalloproteinases (MMPs), which are involved in the degradation of extra cells and metastatic spread, and promote tumor invasion and metastasis. Experimental research has also shown the effectiveness of THC in various cancers such as breast cancer, prostate cancer, colon cancer, and skin cancer. It is important to note that THC increases the therapeutic index of traditional chemotherapeutics, where they show synergistic interactions and counteract drug resistance mechanisms, which is a key obstacle in clinical oncology. THC has better physiological stability and bioavailability compared to its parent molecule, a characteristic that alleviates one of the greatest translational limitations of curcumin. This review highlights the molecular processes underlying the anticancer action of THC, its possible use as a single agent and as an adjuvant to already established chemotherapeutic protocols, and the translational issues that need to be overcome to achieve clinical acceptance. Together, the existing evidence supports THC as an attractive future cancer therapeutic with the potential to improve treatment outcomes and overcome drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.